FDA Orange Book · active-ingredient family
Teduglutide
Teduglutide is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:GATTEX KIT · NDA 203441
1
Brand (NDA)
0
Generics (ANDA)
4
Listed patents
1
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| GATTEX KITRLD | TAKEDA PHARMS USA | NDA 203441 | — | Dec 21, 2012 |
Marketing exclusivity (1)
- ODE-240Orphan-drug exclusivity (7 years)
May 16, 2026
1 mo ago
Listed patents (4)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9060992 | Nov 01, 2025 | 8 mo ago | U-1320Delisted |
| 7847061 | Nov 01, 2025 | 8 mo ago | U-1320Delisted |
| 7847061*PED | May 01, 2026 | 2 mo ago | |
| 9060992*PED | May 01, 2026 | 2 mo ago |
Teduglutide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

